Macquarie Group
ELEV

Macquarie Group’s Elevation Oncology ELEV Stock Holding History

Macquarie Group’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,274
Closed -$7 – 1968
2024
Q1 		$7 Buy
+1,274
New +$4.13K ﹤0.01% 1745

Other funds holding ELEV

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Macquarie Group's ELEV Position: Q2 2024 in Review

Macquarie Group sold out of Elevation Oncology (ELEV) in Q2 2024, closing a stake of 1,274 shares — an estimated $7 sold.

Macquarie Group first reported a position in ELEV in Q1 2024 and held it in 1 quarter. The position peaked at $7 in Q1 2024. 81 funds tracked by Wall St. Rank hold ELEV as of Q2 2024.

  • Macquarie Group reported no remaining Elevation Oncology position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 1,274 Elevation Oncology shares in Q2 2024, an estimated $7.
  • Macquarie Group first reported a position in Elevation Oncology in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Elevation Oncology position peaked at $7 in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.